Prostate‐Specific Antigen Dynamics and Bone Predominance as Predictors of Efficacy in Radium‐223 Treatment for Castration‐Resistant Prostate Cancer

Kohei Hashimoto has received honoraria from Astellas, Janssen, Bayer, and AstraZeneca. Naoya Masumori received honoraria from Astellas, Janssen, Takeda, Kissei, Kyorin, and AstraZeneca, and research funding from Astellas, Ono, Daiichisankyo, Takeda, and Kissei. Tetsuya Shindo, Ko Kobayashi, and Toshiaki Tanaka had no conflicts of interest. Ko Kobayashi is an Editorial member, Naoya Masumori, Editor-in-Chief, and Kohei Hashimoto, Managing Editor of the International Journal of Urology, are co-authors of this article. They were excluded from all editorial decisions regarding the acceptance and publication of this manuscript.